Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 7/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 5/20 | 0.47 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.47 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.47 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.44 |
| ▸ | NPY1R | P25929 | 1/20 | 0.41 |
| ▸ | NPY2R | P49146 | 1/20 | 0.41 |
| ▸ | NPY4R | P50391 | 1/20 | 0.41 |
| ▸ | FURIN | P09958 | 1/20 | 0.41 |
| ▸ | PCSK6 | P29122 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1711732 | 1.00 | CPB2 (0.47) | CPB2FOLH1ERAP2ERAP1LNPEP | |
| SCHEMBL1711325 | 1.00 | CPB2 (0.47) | CPB2FOLH1ERAP2ERAP1LNPEP | |
| SCHEMBL1711321 | 1.00 | CPB2 (0.47) | CPB2FOLH1ERAP2ERAP1LNPEP | |
| Hydrochloric Acid SCHEMBL11366046 | 0.99 | CPB2 (0.47) | CPB2FOLH1ERAP2ERAP1LNPEP | |
| SCHEMBL31257001 | 0.95 | CPB2 (0.45) | CPB2FOLH1ERAP2ERAP1LNPEP | |
| SCHEMBL30284335 | 0.95 | CPB2 (0.45) | CPB2FOLH1ERAP2ERAP1LNPEP | |
| SCHEMBL30973961 | 0.93 | FOLH1 (0.56) | CPB2FOLH1ERAP2ERAP1LNPEP | |
| SCHEMBL29782763 | 0.92 | FOLH1 (0.51) | CPB2FOLH1ERAP2ERAP1LNPEP | |
| SCHEMBL1711315 | 0.92 | FOLH1 (0.54) | CPB2FOLH1ERAP2ERAP1LNPEP | |
| SCHEMBL1711313 | 0.92 | FOLH1 (0.54) | CPB2FOLH1ERAP2ERAP1LNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 337 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121574249-A | Anti-CD 45 antibodies and conjugates thereof | VOR生物制药股份有限公司 | 2026-02-27 | — | — | CN | claimed |
| WO-2026041129-A1 | LIGAND-CYTOTOXICITY DRUG CONJUGATES AND PHARMACEUTICAL USES THEREOF | HANSOH BIO LLC (US) | 2026-02-26 | — | — | WO | claimed |
| EP-4684807-A1 | LINKER AND USE THEREOF IN LIGAND DRUG CONJUGATE | Duality Biologics (Shanghai) Co., Ltd. (CN) | 2026-01-28 | — | — | EP | claimed |
| US-12534722-B2 | Euglobulin-based method for determining the biological activity of defibrotide | GENTIUM S.R.L. (IT) | 2026-01-27 | — | — | US | claimed |
| US-20260014270-A1 | ANTI-CEACAM5 ANTIBODY-DRUG CONJUGATE AND METHOD FOR PREPARATION AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2026-01-15 | — | — | US | claimed |
| EP-4667495-A2 | BIOACTIVE MOLECULE CONJUGATE, PREPARATION METHOD AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2025-12-24 | — | — | EP | claimed |
| US-20250346606-A1 | CAMPTOTHECIN COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2025-11-13 | — | — | US | claimed |
| US-20250281631-A1 | ANTIBODY-DRUG CONJUGATES AND PREPARATION METHODS AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2025-09-11 | — | — | US | claimed |
| EP-4612124-A1 | AZOTOMYCIN PRODRUGS WITH PREFERENTIAL TUMOR DELIVERY | The Johns Hopkins University (US) | 2025-09-10 | — | — | EP | claimed |
| EP-4601701-A1 | ANTIBODY-DRUG CONJUGATE BINDING TO HUMAN PTK7 AND METHOD FOR PREPARATION AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2025-08-20 | — | — | EP | claimed |
| US-11236328-B2 | Euglobulin-based method for determining the biological activity of defibrotide | GENTIUM S.R.L. (IT) | 2022-02-01 | — | — | US | claimed |
| US-7705045-B2 | compounds comprising a specifier linked to two or more of the same or different leaving groups via a self-eliminating multiple release spacer or spacer system, which compounds upon a single activation step, in particular removal or transformation of the specifier, release two or more leaving groups | SYNTARGA, B.V. (NL) | 2010-04-27 | — | — | US | claimed |
| EP-1370298-B1 | ELONGATED AND MULTIPLE SPACERS IN ACTIVATIBLE PRODRUGS | SYNTARGA BV (NL) | 2008-10-08 | — | — | EP | claimed |
| US-7223837-B2 | Anticancer prodrugs, enhance enzymatic activation rates | SYNTARGA B.V. (NL) | 2007-05-29 | — | — | US | claimed |
| US-20060116422-A1 | Prodrugs built as multiple self-elimination-release spacers | SYNTARGA B.V. (NL) | 2006-06-01 | — | — | US | claimed |
| EP-1560599-A1 | PRODRUGS BUILT AS MULTIPLE SELF-ELIMINATION-RELEASE SPACERS | Syntarga B.V. (NL) | 2005-08-10 | — | — | EP | claimed |
| US-20040121940-A1 | Elongated and multiple spacers in activatible produgs | BYONDIS B.V. (NL) | 2004-06-24 | — | — | US | claimed |
| WO-2004043493-A1 | PRODRUGS BUILT AS MULTIPLE SELF-ELIMINATION-RELEASE SPACERS | SYNTARGA B.V. (NL) | 2004-05-27 | — | — | WO | claimed |
| EP-1370298-A1 | ELONGATED AND MULTIPLE SPACERS IN ACTIVATIBLE PRODRUGS | Syntarga B.V. (NL) | 2003-12-17 | — | — | EP | claimed |
| WO-2002083180-A1 | ELONGATED AND MULTIPLE SPACERS IN ACTIVATIBLE PRODRUGS | SYNTARGA B.V. (NL) | 2002-10-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250346606-A1 | CAMPTOTHECIN COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | WEE1, WEE2, PCLAF | CPB2 2488/4885FOLH1 469/4885ERAP2 3014/4885 |
| US-20060116422-A1 | Prodrugs built as multiple self-elimination-release spacers | DNPEP, GUSB, APEH | CPB2 75/4885FOLH1 10/4885ERAP2 106/4885 |
| US-20040121940-A1 | Elongated and multiple spacers in activatible produgs | PLG, KLK1, PKM | CPB2 602/4885FOLH1 77/4885ERAP2 1536/4885 |
| US-20260014270-A1 | ANTI-CEACAM5 ANTIBODY-DRUG CONJUGATE AND METHOD FOR PREPARATION AND USE THEREOF | TOP1, TNFSF10, CD2 | CPB2 3915/4885FOLH1 387/4885ERAP2 4371/4885 |
| US-12534722-B2 | Euglobulin-based method for determining the biological activity of defibrotide | FGB, PLG, F2 | CPB2 244/4885FOLH1 1337/4885ERAP2 1936/4885 |
| US-20250281631-A1 | ANTIBODY-DRUG CONJUGATES AND PREPARATION METHODS AND USE THEREOF | TOP1, TOP2A, TOP2B | CPB2 3524/4885FOLH1 132/4885ERAP2 3204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.